Cardiovascular disease and cancer are associated with an aging population and share common risk factors. Patients with a cancer history have a 2-3-fold higher risk of the acute coronary syndrome (ACS), which lasts up to 10 years following cancer diagnosis. Patients with both cancer and cardiovascular disease have worse survival rates than those with cancer alone. Furthermore, the occurrence of myocardial infarction accelerates cancer progression and exacerbates cancer patient survival. In this scenario, understanding interactions between cancer and cardiovascular disease is vital to improve the prognosis of patients with cancer and cardiovascular disease comorbidity. Besides, recent advances in treatment have led to improved survival of cancer patients but have also increased mortality due to treatment side effects. Cardiovascular diseases are the most frequent side effects and largely threatens and health of cancer survivors. Cardiotoxicity, a relatively new term in the medical literature, refers to the impact of cancer therapies on the cardiovascular system. There is an increasingly recognized consensus that side effects lead to premature morbidity and death among cancer survivors. Understanding the mechanisms of cancer therapy-associated cardiotoxicity will be fundamental to develop novel therapeutics that can protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies.
The aim of this Research Topic is to bring together a series of papers that gives an update on interactions between cancer and cardiovascular disease and highlight recent insights on the mechanisms and treatments of cancer therapy-associated cardiotoxicity. The study of how cancer and cardiovascular disease interacted with each other is especially welcomed. Besides, studies delineating the signaling mechanisms and potential rescue strategies of cancer therapies such as anthracycline, trastuzumab, VEGF inhibitors, immune checkpoint inhibitors or radiation therapy in inducing cardiac dysfunction, refractory hypertension, and vasospastic and thromboembolic ischemia, as well as rhythm disturbances are also very welcome research topics.
Topics related to this theme include:
1) Common risk factors for heart failure and cancer.
2) Cancer and cardiovascular disease interaction.
3) Cardiovascular toxicities associated with immune checkpoint inhibitors.
4) Prevention and treatment of cardiac dysfunction induced by cancer therapy.
5) Vascular Cardio-Oncology: vascular endothelial growth factor inhibitors and hypertension.
6) Cardio-protection in cancer therapy: novel insights with anthracyclines
7) Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell (review).
8) Cardiac arrhythmia considerations of hormone cancer therapies.
Cardiovascular disease and cancer are associated with an aging population and share common risk factors. Patients with a cancer history have a 2-3-fold higher risk of the acute coronary syndrome (ACS), which lasts up to 10 years following cancer diagnosis. Patients with both cancer and cardiovascular disease have worse survival rates than those with cancer alone. Furthermore, the occurrence of myocardial infarction accelerates cancer progression and exacerbates cancer patient survival. In this scenario, understanding interactions between cancer and cardiovascular disease is vital to improve the prognosis of patients with cancer and cardiovascular disease comorbidity. Besides, recent advances in treatment have led to improved survival of cancer patients but have also increased mortality due to treatment side effects. Cardiovascular diseases are the most frequent side effects and largely threatens and health of cancer survivors. Cardiotoxicity, a relatively new term in the medical literature, refers to the impact of cancer therapies on the cardiovascular system. There is an increasingly recognized consensus that side effects lead to premature morbidity and death among cancer survivors. Understanding the mechanisms of cancer therapy-associated cardiotoxicity will be fundamental to develop novel therapeutics that can protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies.
The aim of this Research Topic is to bring together a series of papers that gives an update on interactions between cancer and cardiovascular disease and highlight recent insights on the mechanisms and treatments of cancer therapy-associated cardiotoxicity. The study of how cancer and cardiovascular disease interacted with each other is especially welcomed. Besides, studies delineating the signaling mechanisms and potential rescue strategies of cancer therapies such as anthracycline, trastuzumab, VEGF inhibitors, immune checkpoint inhibitors or radiation therapy in inducing cardiac dysfunction, refractory hypertension, and vasospastic and thromboembolic ischemia, as well as rhythm disturbances are also very welcome research topics.
Topics related to this theme include:
1) Common risk factors for heart failure and cancer.
2) Cancer and cardiovascular disease interaction.
3) Cardiovascular toxicities associated with immune checkpoint inhibitors.
4) Prevention and treatment of cardiac dysfunction induced by cancer therapy.
5) Vascular Cardio-Oncology: vascular endothelial growth factor inhibitors and hypertension.
6) Cardio-protection in cancer therapy: novel insights with anthracyclines
7) Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell (review).
8) Cardiac arrhythmia considerations of hormone cancer therapies.
